BiOxyDyn Revenue and Competitors
Estimated Revenue & Valuation
- BiOxyDyn's estimated annual revenue is currently $3M per year.
- BiOxyDyn's estimated revenue per employee is $251,000
Employee Data
- BiOxyDyn has 12 Employees.
- BiOxyDyn grew their employee count by 0% last year.
BiOxyDyn's People
Name | Title | Email/Phone |
---|
BiOxyDyn Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is BiOxyDyn?
Bioxydyn is a world leading global imaging contract research organisation (CRO) providing magnetic resonance imaging services to support clinical drug development and is also developing diagnostic products for routine clinical use. We specialise in Oxygen-Enhanced MRI (OE-MRI), Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion MRI. Our range of expertise, operational capability and intellectual property allows us to offer advanced imaging services across a broad range of disease areas including lung, rheumatology, neurology and oncology. We are a rapidly growing company that is actively recruiting. Please get in touch if you would like to know more about joining us.
keywords:N/AN/A
Total Funding
12
Number of Employees
$3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BiOxyDyn News
Bioxydyn Ltd. Zionexa; Imabiotech; BRAINOMIX. A biomarker is a biological molecule found in tissue, blood, or other body fluids, which marks the...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 12 | -20% | N/A |
#2 | $1M | 12 | 9% | N/A |
#3 | $0.7M | 12 | 20% | N/A |
#4 | $0.6M | 12 | 9% | N/A |
#5 | $0.6M | 12 | 9% | N/A |